Results 101 to 110 of about 64,926 (256)

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Validity of Plasma Neuropeptide Y in Combination with Clinical Factors in Predicting Neuralgia Following Herpes Zoster

International Journal of General Medicine
Dan Wu,1 Fang Li,2 Feifei Yang,3 Jun Liu4 1Department of Dermatology, Peking University First Hospital Ningxia Women and Children’s Hospital (Ningxia Hui Autonomous Region Maternal and Child Health Hospital), Yinchuan City, Ningxia Hui Autonomous Region,
Wu D, Li F, Yang F, Liu J
doaj  

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Neuronal and ion channel mechanisms of noxious heat sensing in mammals: A puzzle of sensory physiology and pharmacology

British Journal of Pharmacology, EarlyView.
Transient receptor potential vanilloid 1 (TRPV1) was the first noxious heat‐sensitive channel discovered. In rodents, its role is robust in the heat response of the cell body of polymodal nociceptors, but surprisingly small in that of the peripheral terminals in the skin.
Gábor Pethő, Peter W. Reeh
wiley   +1 more source

Gut microbiota as a novel therapeutic target for eating disorders and obesity

British Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė, Victor Mathis, Emmanuel Darcq, Aurelijus Burokas, Elena Martín‐García, Rafael Maldonado   +5 more
wiley   +1 more source

Pro-neuropeptide Y as a circulating biomarker for poor prognosis in prostate cancer. [PDF]

Sci Rep
Djusberg E, Lundquist K, Lundholm M, Josefsson A, Karlsson CT, Schwenk JM, Brattsand M, Bergh A, Wikström P.   +8 more
europepmc   +1 more source

Targeting peroxynitrite production in a model of persistent temporomandibular disorder comorbid with migraine

British Journal of Pharmacology, EarlyView.
Background and Purpose The persistence of temporomandibular disorders (TMDs), particularly myogenous, in a person with migraine can lead to exacerbated clinical outcomes and limited response to treatment. The pro‐nociceptive reactive nitroxidative species, peroxynitrite, is involved in migraine mechanisms, but little is known of its role in this ...
Simon Akerman, Ana Belen Salinas‐Abarca, Wei Guo, Daniela Salvemini, Marcela Romero‐Reyes   +4 more
wiley   +1 more source

Age-dependent increase in peripheral neuropeptide Y with no cross-sectional link to depression. [PDF]

Acta Neuropsychiatr
Dahlaki M, Alam MDZ, Nyholm Nielsen M, Nørmølle Buttenschon H, Winterdahl M.   +4 more
europepmc   +1 more source

pH-dependent structural dynamics of neuropeptide Y in aqueous solution. [PDF]

PLoS One
Nguyen HT, Spehr M, Bondar AN, Carloni P.   +3 more
europepmc   +1 more source

Weight loss with atogepant in the long‐term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open‐label, 156‐week extension study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess weight loss with atogepant 60 mg once daily during long‐term treatment of chronic migraine (CM) and episodic migraine (EM) among participants previously failed by two to four classes of conventional oral preventive medications.
Dale S. Bond, Jonathan H. Smith, Alexandra Sinclair, Peter J. Goadsby, Jessica Ailani, Yingyi Liu, Rosa De Abreu Ferreira, Brett Dabruzzo, Joel M. Trugman, B. Lee Peterlin   +9 more
wiley   +1 more source